Modulating the microbiota in inflammatory bowel diseases: Prebiotics, probiotics or faecal transplantation?

Proceedings of the Nutrition Society

Volumn 73, Issue 4, 2014, Pages 490-497

  Verbeke, Kristin A ^a,b   Boesmans, Leen ^a,b   Boets, Eef ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b LEUVEN FOOD SCIENCE AND NUTRITION RESEARCH CENTRE LFORCE   (Belgium)

Author keywords

Faecal microbiota transplantation; Inflammatory bowel diseases; Prebiotics; Probiotics

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; MESALAZINE; PREBIOTIC AGENT; PROBIOTIC AGENT; VSL3;

CLOSTRIDIUM; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ESCHERICHIA COLI; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HUMAN; ILEITIS; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LACTOBACILLUS JOHNSONII; LACTOBACILLUS RHAMNOSUS; NONHUMAN; PATHOGENESIS; REMISSION; T LYMPHOCYTE; TRANSPLANTATION; ULCERATIVE COLITIS; ANIMAL; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; INFLAMMATORY BOWEL DISEASES; INTESTINE; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; PEPTOCLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI;

ANIMALS; CLOSTRIDIUM DIFFICILE; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; MICROBIOTA; PREBIOTICS; PROBIOTICS;

EID: 84927910670     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665114000639     Document Type: Conference Paper

References (104)

1. Nikolaus S & Schreiber S (2007) Diagnostics of inflammatory bowel disease. Gastroenterology 133, 1670-1689.
2. Asquith M & Powrie F (2010) An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med 207, 1573-1577.
3. Strober W, Fuss I & Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117, 514-521.
4. Manichanh C, Borruel N, Casellas F et al. (2012) The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9, 599-608.
5. Faith JJ, Guruge JL, Charbonneau M et al. (2013) The long-term stability of the human gut microbiota. Science 341, 44-U53.
6. Kawada M, Arihiro A & Mizoguchi E (2007) Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 13, 5581-5593.
7. Rutgeerts P, Goboes K, Peeters M et al. (1991) Effect of fecal stream diversion on recurrence of Crohn's-disease in the neoterminal ileum. Lancet 338, 771-774.
8. D'Haens GR, Geboes K, Peeters M et al. (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114, 262-267.
9. Khan KJ, Ullman TA, Ford AC et al. (2011) Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106, 661-673.
10. Sartor RB (1997) Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 3, 230-235.
11. Berry D & Reinisch W (2013) Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol 27, 47-58.
12. Manichanh C, Rigottier-Gois L, Bonnaud E et al. (2006) Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55, 205-211.
13. Qin JJ, Li RQ, Raes J et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-U70.
14. Frank DN, Amand ALS, Feldman RA et al. (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104, 13780-13785.
15. Lepage P, Hasler R, Spehlmann ME et al. (2011) Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141, 227-236.
16. Sokol H, Pigneur B, Watterlot L et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105, 16731-16736.
17. Machiels K, Joossens M, Sabino J et al. (2012) Bacterial dysbiosis in ulcerative colitis patients differs from Crohn's disease patients. Gastroenterology 142, S46.
18. Hooper LV, Littman DR & Macpherson AJ (2012) Interactions between the microbiota and the immune system. Science 336, 1268-1273.
19. Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61, 918-932.
20. FAO/WHO (2002) Guidelines for the Evaluation of Probiotics in Food. Available at: http://ftp.fao.org/es/esn/food/wgreport2.pdf, Accessed June 2014.
21. World Gastroenterology Organisation (2011) Probiotics and prebiotics. Available at: http://www.worldgastroenterology. org/assets/export/userfiles/Probiotics-FINAL-20110116. pdf
22. Bengmark S (1998) Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 42, 2-7.
23. Kruis W, Schutz E, Fric P et al. (1997) Double-blind comparison of an oral Escherichia coli preparation and mesala-zine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11, 853-858.
24. Jonkers D & Stockbrugger R (2003) Probiotics and inflammatory bowel disease. J R Soc Med 96, 167-171.
25. Marteau P, Seksik P & Shanahan F (2003) Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 17, 47-61.
26. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, pro-biotics, and prebiotics. Gastroenterology 126, 1620-1633.
27. Atlas RM (1999) Probiotics-snake oil for the new millennium? Environ Microbiol 1, 377-382.
28. Rembacken BJ, Snelling AM, Hawkey PM et al. (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354, 635-639.
29. Kruis W, Fric P, Pokrotnieks J et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623.
30. Matthes H, Krummenerl T, Giensch M et al. (2010) Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 10, 13.
31. Tursi A, Brandimarte G, Giorgetti GM et al. (2004) Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesala-zine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10, I126-I131.
32. Bibiloni R, Fedorak RN, Tannock GW et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100, 1539-1546.
33. Huynh HQ, deBruyn J, Guan LL et al. (2009) Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 15, 760-768.
34. Miele E, Pascarella F, Giannetti E et al. (2009) Effect of a probiotic preparation (VSL# 3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104, 437-443.
35. Sood A, Midha V, Makharia GK et al. (2009) The pro-biotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7, 1202-1209.
36. Ng SC, Plamondon S, Kamm MA et al. (2010) Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 16, 1286-1298.
37. Tursi A, Brandimarte G, Papa A et al. (2010) Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105, 2218-2227.
38. Venturi A, Gionchetti P, Rizzello F et al. (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13, 1103-1108.
39. Peddi PKK, Ombiga J, Willert R et al. (2009) Randomised, double-blinded, placebo-controlled study of VSL#3 versus placebo in the maintenance of remission in Crohn's disease. J Gastroenterol Hepatol 24, A317.
40. Campieri M, Rizzello F, Venturi A et al. (2000) Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesala-mine. Gastroenterology 118, A781.
41. Gionchetti P, Rizzello F, Venturi A et al. (2000) Oral bac-teriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119, 305-309.
42. Gionchetti P, Rizzello F, Helwig U et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124, 1202-1209.
43. Mimura T, Rizzello F, Helwig U et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53, 108-114.
44. Shen B, Brzezinski A, Fazio VW et al. (2005) Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 22, 721-728.
45. Bron PA, van Baarlen P & Kleerebezem M (2011) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10, 66-78.
46. Jonkers D, Penders J, Masclee A et al. (2012) Probiotics in the management of inflammatory bowel disease a systematic review of intervention studies in adult patients. Drugs 72, 803-823.
47. Shen J, Zuo ZX & Mao AP (2014) Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 20, 21-35.
48. Zocco MA, Dal Verme LZ, Cremonini F et al. (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23, 1567-1574.
49. Prantera C, Scribano ML, Falasco G et al. (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51, 405-409.
50. Schultz M, Timmer A, Herfarth HH et al. (2004) Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 4, 5.
51. Bousvaros A, Guandalini S, Baldassano RN et al. (2005) A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 11, 833-839.
52. Kuisma J, Mentula S, Jarvinen H et al. (2003) Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. AlimentPharmacol Ther 17, 509-515.
53. Marteau P, Lemann M, Seksik P et al. (2006) Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55, 842-847.
54. Van Gossum A, Dewit O, Louis E et al. (2007) Multicenter randomized-control led clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 13, 135-142.
55. Guslandi M, Mezzi G, Sorghi M et al. (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45, 1462-1464.
56. Bourreille A, Cadiot G, le Dreau G et al. (2013) Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 11, 982-987.
57. Floch MH, Walker WA, Madsen K et al. (2011) Recommendations for probiotic use-2011 update. J Clin Gastroenterol 45, S168-S171.
58. Dotan I (2010) New serologic markers for inflammatory bowel disease diagnosis. Dig Dis 28, 418-423.
59. Oelschlaeger TA (2010) Mechanisms of probiotic actions-a review. Int J Med Microbiol 300, 57-62.
60. Servin AL (2004) Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. Fems Microbiol Rev 28, 405-440.
61. Veerappan GR, Betteridge J & Young PE (2012) Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep 14, 324-333.
62. Caballero-Franco C, Keller K, De Simone C et al. (2007) The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol-Gastrointest Liver Physiol 292, G315-G322.
63. Imaoka A, Shima T, Kato K et al. (2008) Anti-inflammatory activity of probiotic bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol 14, 2511-2516.
64. Jeon SG, Kayama H, Ueda Y et al. (2012) Probiotic Bifidobacterium breve Induces IL-10-producing Tr1 cells in the colon. Plos Pathog 8(5), e1002714.
65. Barletta B, Rossi G, Schiavi E et al. (2013) Probiotic VSL#3-induced TGF-beta ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa. Mol Nutr Food Res 57, 2233-2244.
66. Borthakur A, Bhattacharyya S, Kumar A et al. (2013) Lactobacillus acidophilus alleviates platelet-activating factor-induced inflammatory responses in human intestinal epithelial cells. Plos One 8(10), e75664.
67. Rizzello V, Bonaccorsi I, Dongarra ML et al. (2011) Role of natural killer and dendritic cell crosstalk in immunomodulation by commensal bacteria probiotics. J Biomed Biotechnol 2011, 473097.
68. Lindsay JO, Whelan K, Stagg AJ et al. (2006) Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55, 348-355.
69. Benjamin JL, Hedin CRH, Koutsoumpas A et al. (2011) Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 60, 923-929.
70. Joossens M, De Preter V, Ballet V et al. (2011) Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial. Gut 61, 958.
71. De Preter V, Joossens M, Ballet V et al. (2013) Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial. Clin Transl Gastroenterol 4, e30.
72. Schwab M, Reynders V, Ulrich S et al. (2006) PPAR gamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 11, 1801-1811.
73. Viladomiu M, Hontecillas R, Yuan LJ et al. (2013) Nutritional protective mechanisms against gut inflammation. J Nutr Biochem 24, 929-939.
74. Annese V, Rogai F, Settesoldi A et al. (2012) PPAR gamma in inflammatory bowel disease. PPAR Res 2012, 620839.
75. Maslowski KM, Vieira AT, Ng A et al. (2009) Regulation of inflammatory responses by gut microbiota and chemoat-tractant receptor GPR43. Nature 461, 1282-1286.
76. Bindels LB, Dewulf EM & Delzenne NM (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34, 226-232.
77. Smith PM, Howitt MR, Panikov N et al. (2013) The microbial metabolites, short-chain fatty acids, regulate colonic T-reg cell homeostasis. Science 341, 569-573.
78. Singh N, Gurav A, Sivaprakasam S et al. (2014). Activation of Gpr109a, receptor for Niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40, 128-139.
79. Looijer-Van Langen MACL & Dieleman LA (2009) Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 15, 454-462.
80. Borody TJ & Campbell J (2012) Fecal microbiota transplantation techniques, applications, and issues. Gastro-enterol Clin North Am 41, 781-803.
81. Grehan MJ, Borody TJ, Leis SM et al. (2010) Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 44, 551-561.
82. Eiseman B, Silen W, Bascom GS et al. (1958) Fecal enema as an adjunct in the treatment of Pseudomembranous Enterocolitis. Surgery 44, 854-859.
83. Miyajima F, Roberts P, Swale A et al. (2011) Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the united kingdom. Plos One 6(8), e22804.
84. van Nood E, Vrieze A, Nieuwdorp M et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368, 407-415.
85. Rea MC, Sit CS, Clayton E et al. (2010) Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci USA 107, 9352-9357.
86. Anderson JL, Edney RJ & Whelan K (2012) Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36, 503-516.
87. Borody T, Wettstein A, Campbell J et al. (2012) Fecal microbiota transplantation in ulcerative colitis: review of 24 years experience. Am J Gastroenterol 107, S665.
88. Kunde S, Pham A, Bonczyk S et al. (2013) Safety, toler-ability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Ped Gastroenterol Nutr 56, 597-601.
89. Kump PK, Groechenig HP, Lackner S et al. (2013) Alteration of intestinal Dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19, 2155-2165.
90. Borody TJ, Brandt LJ & Paramsothy S (2014) Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 30, 97-105.
91. Aroniadis OC & Brandt LJ (2013) Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 29, 79-84.
92. Rubin DT (2013) Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol 108, 1631-1633.
93. Angelberger S, Reinisch W, Makristathis A et al. (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal Microbiota transplantation. Am J Gastroenterol 108, 1620-1630.
94. Arumugam M, Raes J, Pelletier E et al. (2011) Enterotypes of the human gut microbiome. Nature 473, 174-180.
95. Smits LP, Bouter KEC, De Vos WM et al. (2013) Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145, 946-953.
96. Vermeire S, Joossens M, Verbeke K et al. (2012) Pilot study on the safety and efficacy of faecal microbiota transplantation in refractory Crohn's disease. Gastroenterology 142, S360.
97. De Leon LM, Watson JB & Kelly CR (2013) Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 11, 1036-1038.
98. Brandt LJ, Aroniadis OC, Mellow M et al. (2012) Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107, 1079-1087.
99. Brandt LJ & Aroniadis OC (2013) An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endoscopy 78, 240-249.
100. Damman CJ, Miller SI, Surawicz CM et al. (2012) The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 107, 1452-1459.
101. Turnbaugh PJ, Ridaura VK, Faith JJ et al. (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized Gnotobiotic mice. Sci Transl Med 1(6):6ra14.
102. Hamilton MJ, Weingarden AR, Sadowsky MJ et al. (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107, 761-767.
103. Petrof EO, Gloor GB, Vanner SJ et al. (2013) Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 1, 3.
104. Shanahan F & Quigley EMM (2014) Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology 146, 1554-1563.